Martin Jdersten

List of Publications by Citations

17 papers	1,166 citations	13 h-index	25 g-index
25 ext. papers	1,610 ext. citations	7.4 avg, IF	3.46 L-index

#	Paper	IF	Citations
17	TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. *Journal of Clinical Oncology*, **2011**, 29, 1971-9	2.2	342
16	SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. *Blood*, **2015**, 126, 233-41	2.2	269
15	Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. *Blood*, **2005**, 106, 803-11	2.2	171
14	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. *Nature Medicine*, **2020**, 26, 1549-1556	50.5	118
13	Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. *Haematologica*, **2009**, 94, 1762-6	6.6	72
12	Mutations in histone modulators are associated with prolonged survival during azacitidine therapy. *Oncotarget*, **2016**, 7, 22103-15	3.3	35
11	Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations. *Haematologica*, **2017**, 102, 498-508	6.6	28
10	The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. *Blood Advances*, **2020**, 4, 1094-1101	7.8	26
9	Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. *Blood*, **2019**, 134, 1558-1561	2.2	21
8	Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register. *British Journal of Haematology*, **2018**, 181, 614-627	4.5	20
7	New clues to the molecular pathogenesis of myelodysplastic syndromes. *Experimental Cell Research* , **2010**, 316, 1390-6	4.2	17
6	Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome. *Nature Cell Biology*, **2020**, 22, 526-533	23.4	16
5	Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study. *British Journal of Haematology*, **2021**, 192, 474-483	4.5	4
4	Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation. *Leukemia and Lymphoma*, **2021**, 1-4	1.9	1
3	Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study. *Leukemia and Lymphoma*, **2021**, 62, 1973-1981	1.9	0
2	Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes. *European Journal of Haematology*, **2021**, 107, 219-228	3.8	0
1	Mutations in Histone Modulators Are Associated with Prolonged Survival during Azacitidine Therapy. *Blood*, **2015**, 126, 2839-2839	2.2	